FCRL3 and myeloid sarcoma: Among these, highly expressed CR1 and WARS were associated with an increased risk of MS, while highly expressed TNFRSF1A, FCRL3, TYMP, PGLYRP1, CD59, IDUA, and ARHGAP1 were associated with a decreased risk of MS (Fig. 3A and SI Appendix, Fig. S1).